Literature DB >> 9671004

Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction.

F Fath-Ordoubadi1, D Pagano, N V Marinho, B E Keogh, R S Bonser, P G Camici.   

Abstract

Chronic postischemic left ventricular (LV) dysfunction can improve following coronary revascularization (hibernating myocardium). However, it is not clear whether the severity of LV dysfunction determines functional outcome after revascularization and the accuracy of tests to predict myocardial viability. We studied 47 patients with coronary artery disease and chronic LV dysfunction. Before coronary bypass, patients underwent (18F)2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) during euglycemic hyperinsulinemic clamp to assess viability. Global and regional LV function were assessed before and 4 to 6 months after surgery. Patients were arbitrarily divided into 2 groups with moderate and severe LV dysfunction. Group 1 (n = 26) had an ejection fraction (EF) of < or = 30% and group 2 (n = 21) > 30%. After bypass, the EF (22+/-6% vs 31+/-10%; p <0.0001) and global wall motion score (WMS) (2.05+/-0.39 vs 1.56+/-0.34; p <0.001) improved in group 1, whereas the EF (43+/-9% vs 43+/-12%; p = NS) was unchanged in group 2, although WMS tended to improve (1.42+/-0.38 vs 1.32+/-0.39; p = 0.09). The proportion of dysfunctional segments (72% vs 32%; p <0.0001) and FDG uptake in these segments (0.44+/-0.15 vs 0.34+/-0.15 micromol/g/min, p <0.0001) were greater in group 1 than in group 2. The baseline EF influenced the predictive accuracy of PET, with highest positive predictive accuracy in group 2 and highest negative predictive accuracy in group 1. Thus, coronary revascularization has the potential for greatest benefit in patients with the most severe dysfunction, but with evidence of viability, and the entity of LV dysfunction affects the predictive accuracy of viability studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671004     DOI: 10.1016/s0002-9149(98)00241-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Positron emission tomography and myocardial imaging.

Authors:  P G Camici
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Hibernating myocardium.

Authors:  R Schulz; G Heusch
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

3.  PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting.

Authors:  Heinrich R Schelbert; Robert Beanlands; Frank Bengel; Juhani Knuuti; Marcelo Dicarli; Josef Machac; Randolph Patterson
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

Review 4.  Surgery for hibernation.

Authors:  J Pepper
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

Review 5.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

Review 6.  Lipoprotein (a) and stroke.

Authors:  H J Milionis; A F Winder; D P Mikhailidis
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

7.  Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction.

Authors:  A F L Schinkel; J J Bax; F B Sozzi; E Boersma; R Valkema; A Elhendy; J R T C Roelandt; D Poldermans
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

Review 8.  Diagnostic and clinical perspectives of fusion imaging in cardiology: is the total greater than the sum of its parts?

Authors:  J J Bax; R S Beanlands; F J Klocke; J Knuuti; A A Lammertsma; M A Schaefers; H R Schelbert; G K Von Schulthess; L J Shaw; G Z Yang; P G Camici
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

9.  Positron emission tomography myocardial perfusion and glucose metabolism imaging.

Authors:  Josef Machac; Stephen L Bacharach; Timothy M Bateman; Jeroen J Bax; Robert Beanlands; Frank Bengel; Steven R Bergmann; Richard C Brunken; James Case; Dominique Delbeke; Marcelo F DiCarli; Ernest V Garcia; Richard A Goldstein; Robert J Gropler; Mark Travin; Randolph Patterson; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 3.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.